YARROW BIOSCIENCE, INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
YARROW BIOSCIENCE, INC. (YARW) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $123.76 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2022-03-17
- YARROW BIOSCIENCE, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2021 was $123.76M, a 0.00% change from fiscal 2020.
- YARROW BIOSCIENCE, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2020 was $123.76M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|
| 2021-12-31 | $123.76M 10-K · filed 2022-03-17 |
| 2020-12-31 | $123.76M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |